Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 44Pancreatic Neoplasms 37Carcinoma, Non-Small-Cell Lung 37Triple Negative Breast Neoplasms 28Ovarian Neoplasms 20Fallopian Tube Neoplasms 19Lung Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Neoplasm Metastasis 11Uterine Cervical Neoplasms 8Melanoma 7Inflammatory Breast Neoplasms 7Esophageal Squamous Cell Carcinoma 6Breast Neoplasms, Male 6Stomach Neoplasms 5Cholangiocarcinoma 5Brenner Tumor 5Pancreatic Adenocarcinoma 4Neoplasms 4Esophageal Neoplasms 4Carcinoma, Transitional Cell 4Adenocarcinoma, Bronchiolo-Alveolar 4Adenocarcinoma of Lung 4Adenocarcinoma Of Esophagus 4Urinary Bladder Neoplasms 3Pleural Effusion, Malignant 3Oropharyngeal Neoplasms 3Nasopharyngeal Carcinoma 3Mouth Neoplasms 3Endometrial Neoplasms 3

Interventions

Gemcitabine 3pembrolizumab 2Leucovorin 2Fluorouracil 24-fluorobenzoyl-TN-14003 2regorafenib 1olaparib 1irinotecan sucrosofate 1Taxes 1Oxaliplatin 1Irinotecan 1Erlotinib Hydrochloride 1Drug Therapy 1BKT140 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Pancreatic Adenocarcinoma × Taxes × Clear all
NCT06576115 2025-11-05

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡